Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019)

Fulcrum Therapeutics (FULC) has 2 years of Preferred Stock Liabilities data on record, last reported at $105.2 million in Q2 2019.

  • On a quarterly basis, Preferred Stock Liabilities rose 75.64% to $105.2 million in Q2 2019 year-over-year; TTM through Jun 2019 was $105.2 million, a 75.64% increase, with the full-year FY2018 number at $79.8 million, changed N/A from a year prior.
  • Preferred Stock Liabilities reached $105.2 million in Q2 2019 per FULC's latest filing, up from $59.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for FULC hit a ceiling of $105.2 million in Q2 2019 and a floor of $59.9 million in Q2 2018.